Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Mutated Opioid Receptors Block Chronic Pain Signals

Technology #z02120

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Opioid receptor at a synapseA general schematic for antagonist’s effects on µ opioid receptorsMutated opioid receptors can block chronic pain signals
Categories
Researchers
Horace H. Loh, Ph.D.
Head of Pharmacolohy, Regents Professor, Frederick and Alice Stark Professor, and Director of Basic Research Center in Molecular & Cell Biology of Drug Addiction
External Link (www.pharmacology.med.umn.edu)
Ping-Yee Law, Ph.D.
Professor of Pharmacology, Research Council Chair of the Basic Research Center in Molecular & Cell Biology of Drug Addiction
External Link (www.pharmacology.med.umn.edu)
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

Isolated nucleic acid molecules encoding mutant .mu. opioid receptors

US Patent Pending 7214534

Chronic Pain Relief Using a Mutant Opioid Receptor

Narcotic analgesics such as morphine for chronic pain treatment have been used widely. However, the prolonged used of morphine for such purposes could lead to many unwarranted side effects, two of which are tolerance and addiction to the drug. Instead of developing stronger narcotic analgesic agents, a complex mutant opioid receptor, the target of morphine action, has been characterized and utilized to accomplish chronic pain relief. 

MN-IP Try and Buy
MN-IP Try and Buy deal terms are available upon request. Contact Raj Udupa for specific details.

Naltrexone and Naloxone to Activate Mutated Opioid Receptor

Experimental data in-vivo shows that the mutation can render classical antagonists to full agonist, such as naloxone and naltrexone which are traditionally used to manage opioid dependence. Using compounds like this to elicit a response rather than block receptors allows receptor mutations to be effective in the treatment of chronic pain. When the mutated receptor is expressed in certain segments of the spinal cord, pain transmission will be blocked with systemic administration of naloxone or naltrexone. This method localizes the pain treatment and reduces the possibility of dependence. This is because activation will take place only on the mutated receptors that are locally distributed. Endogenous receptors will not be affected by this treatment, and therefore, traditional paths to opioid dependence are avoided.